new ann 14-sep11, page-9

just to clarify .....re the double blind process and Primas stage 111 clinical trials ....

.... no one will basically know if they have received cVac or not ....

Double-blind testing is an especially stringent way of conducting an experiment on human subjects....

It attempt to eliminate subjective bias on the part of both experimental subjects and the experimenters.

.... unfortunately 1/2 of those receiving cVac will be on a placebo.... in the aid of ' correct scientific procedure '

... testing on a worldwide populations as Prima will also lead to a much more significant validation of results ... by lessing issues such as environmental factors perhaps influencing results...

Double-blind experiments are held to achieve a higher standard of scientific rigor...... so early release of information goes counter to scientific practice .... and would indeed jeopardize the outcomes validity

Testing cVac through Double-blinding is achieved by formulating the cVac and a placebo to have identical appearance orin it's administrrtion

Patients are randomly assigned to the control or experimental group and given random numbers by a study coordinator ... who also encodes the drugs with matching random numbers.

.... and the critical factor is that neither the patients nor the researchers monitoring the outcome know which patient is receiving which treatment, until the study is over .

It must be noted however ... that studies have been suspended in cases where the tested drug combinations were so effective that it was deemed unethical to continue withholding the findings from the control group, and the general population ....

.... so let's hope that cVac will prove to be one such case .... particularly for cancer sufferers all around the world